Complimentary techniques for determining relative response factor of non- isolated impurities
Understanding the concept behind determining UV RRF of non-isolated impurities using High Performance Liquid Chromatography and Nuclear Magnetic Resonance
The many benefits of outsourcing Stability: A Baxter-Syngene Case study
Learn why Baxter chose to partner with Syngene for Stability studies, the business flow, governance mechanism and metrics that were implemented, which enabled a mutually successful collaboration.
Audit Syngene Virtually
Syngene is using virtual audits to enable clients/regulators experience its capability and infrastructure, without physically visiting the site.
Multidrug combo for companion animals
Learn how Syngene developed and commercialized for its client, a complex palatable dosage form comprising three actives for use in companion animals.
Combating COVID-19 – The Oligonucleotide Way
Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.
Development of degraders: A Medicinal Chemistry perspective
Key considerations for developing protein degraders from a medicinal chemistry perspective regardless of the mechanism of modulation.
Has the Age of Antisense Oligonucleotides Finally Arrived
Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.
Harnessing Targeted Protein Degradation
Read how Syngene’s partnership with a leading Biotech company working in the field of cancer therapy, grew from one small pilot project to over 100 FTEs today.
Your pre-clinical toxicology program needs a strategy
At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies — thereby accelerating the initiation of Clinical trials.
The Dedicated Center- Outsourcing Answer to the Innovation and ROI Challenge in the Biopharmaceutical Industry
Syngene’s dedicated model is the equivalent of having access to a full-fledged pharma company, housed in a single campus with capabilities across small molecules and biologics.